Pressmeddelanden

(Stockholm October 19, 2021) Inhalation Sciences AB (ISAB) has received a new order worth 202 KEUR (2.025 MSEK) from a major inhaled pharma company in China specializing in asthma and COPD treatments for the global market. The order is for ISAB’s PreciseInhale® aerosol generating platform and its in vitro lung simulation module DissolvIt®.

(Stockholm, Sweden, 12 October 2021) In a renewed partnership Karolinska Institutet (KI) in Stockholm will help validate ISAB’s new XposeALI® MP (Micro Perfusion) tool, including using it to test a Mars dust surrogate for the European Space Agency as part of exploring future manned missions to Mars. XposeALI® MP is a highly automated new iteration of ISAB’s current cell culturing module and is expected to make in vitro lung studies simpler, more consistent and more cost-effective – including for biologics, a key priority area for inhaled drug developers.

(Stockholm, Sverige, 29 september, 2021) Inhalation Sciences Sweden AB (ISAB) tillkännager att Redeye fått i uppdrag att utföra regelbunden aktieanalys av företaget. Det strategiska målet är att öka ISABs marknadsprofil och synlighet, samt öka investerares och aktieägares förståelse av verksamheten, dess prestation och framtidsutsikt.  

(Stockholm, Sweden, 29 September, 2021) Inhalation Sciences AB (ISAB) announces today it has commissioned Redeye to produce regular, in-depth stock analyses of the company. The strategic goal is to increase ISAB’s market profile and visibility, enabling investors and stakeholders to develop a better understanding of the business and its performance and prospects.

(Stockholm, Sverige, 26 augusti 2021) Inhalation Sciences AB meddelar att bolagets delårsrapport för det andra kvartalet finns nu tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 26, August, 2021) Inhalation Sciences AB announces that the company's Q2 Report for 2021 (in Swedish) is now available on the company's website.

(Stockholm August 16, 2021) Inhalation Sciences’ US patent protection on its unique aerosol generation system PreciseInhale[® ]has been extended until 2034. Increasing global presence has been a key strategy for ISAB in 2021, with the US as a priority market.

Vid en extra bolagsstämma den 22 juni 2021 beslutades att emittera teckningsoptioner till befintliga aktieägare i Inhalation Sciences. Teckningsoptionerna kommer att tas upp till handel på Spotlight med första handelsdag den 27 juli 2021.

(Stockholm July 5, 2021) Inhalation Research Services (IRS), ISAB’s contract research organization, has signed a contract worth 101 000 EURO (just over 1 million SEK) with a US pharma company. This is the first contract following ISAB’s recent agreements with US lead generating agents specializing in inhalation drug development. If successful, the proof-of-concept research project is expected to lead to a purchase order for the entire PreciseInhale® system and its new mouse exposure module.

Den 2 juni 2021 offentliggjorde Inhalation Sciences Sweden AB ("ISAB" eller "Bolaget") att Bolaget genomfört en riktad emission om ca 2,6 miljoner aktier. Vidare beslutade styrelsen om en emission av teckningsoptioner till samtliga befintliga aktieägare i ISAB. Beslutet godkändes av en extra bolagsstämma den 22 juni 2021. ISAB har idag beslutat att ytterligare senarelägga avstämningsdagen för erhållande av teckningsoptioner till den 12 juli 2021.

Inhalation Sciences Sweden AB (publ) (”Inhalation Sciences”) avhöll den 22 juni 2021 en extra bolagsstämma. Vid stämman fattades bland annat följande beslut.

(Stockholm, Sweden, June 22, 2021) Full enrolment has been reached, on schedule, in ISAB’s clinical trial of its aerosol generating system PreciseInhale[®]- with all 12 patients recruited. CEO Manoush Masarrat: “Clinical validation would make PreciseInhale[®] the first aerosol generation platform that can be used from drug discovery, through preclinical studies, all the way to phase I clinical trials - a major milestone that could open up significant new markets.”

Den 2 juni 2021 offentliggjorde Inhalation Sciences Sweden AB ("ISAB" eller "Bolaget") att Bolaget genomfört en riktad emission om ca 2,6 miljoner aktier. Vidare beslutade styrelsen, under förutsättning av en extra bolagsstämmas godkännande, om en emission av teckningsoptioner till samtliga befintliga aktieägare i ISAB. ISAB har idag beslutat att senarelägga avstämningsdagen för erhållande av teckningsoptioner till den 5 juli 2021.

(Stockholm June 18, 2021) Inhalation Research Services (IRS), the contract research organization of Inhalation Sciences AB, has signed a contract with Stockholm-based research company ISR Immune System Regulation AB worth 898 000 SEK. The contract is for part of the toxicology program of a novel inhaled vaccine against SARS-CoV-2, the virus that causes COIVD-19.

(Stockholm, Sweden, June 16, 2021) The first patient has been enrolled, on schedule, in ISAB’s clinical trial of its aerosol generating system PreciseInhale[®]. CEO Manoush Masarrat: “Clinical validation of PreciseInhale[®] would be transformational for ISAB, opening up new markets and new opportunities for major growth.”

Inhalation Sciences Sweden AB (publ) (”Bolaget”) avhöll den 8 juni 2021 årsstämma. Med anledning av rådande covid-19-pandemi hölls årsstämman endast genom poströstning. Vid stämman fattades bland annat följande beslut.

Aktieägarna i Inhalation Sciences Sweden AB (publ), org.nr 556665-6038 (”Inhalation Sciences” eller ”Bolaget”), med säte i Stockholm, kallas härmed till extra bolagsstämma 22 juni 2021.

Styrelsen för Inhalation Sciences Sweden AB ("ISAB" eller "Bolaget") har idag, med stöd av bemyndigande från årsstämman den 12 maj 2020 och i enlighet med vad som indikerades i Bolagets pressmeddelande den 2 juni 2021, genomfört en riktad nyemission om ca 2,6 miljoner aktier till ett begränsat antal kvalificerade privata investerare (”Riktad emission”). Styrelsen för ISAB har därutöver, under förutsättning av en extra bolagsstämmas godkännande, beslutat om en riktad emission till Daniel Spasic om 150 000 aktier samt en emission av teckningsoptioner till samtliga befintliga aktieägare i ISAB. Genom de riktade emissionerna kan ISAB sammanlagt tillföras ca 27,5 Mkr före emissionskostnader, vilket finansierar Bolagets fortsatta kommersialisering av PreciseInhale®.

Inhalation Sciences Sweden AB ("ISAB" eller "Bolaget") har uppdragit åt Erik Penser Bank att utreda förutsättningarna för att genomföra en riktad kontant nyemission om upp till cirka 2,6 miljoner aktier (den "Riktade emissionen") genom ett accelererat bookbuilding-förfarande ("Bookbuilding-förfarandet"). Vidare avser ISAB att emittera teckningsoptioner vederlagsfritt till Bolagets befintliga aktieägare.

(Stockholm, Sweden, June 1, 2021) On 19-20 May ISAB digitally trained the lab team at Aquilon Pharma to remotely install and operate its new PreciseInhale[®] system, the third remote installation and training project carried out in recent months. Aquilon Pharma founder Professor Didier Cataldo: “With this process, we acquired step-by-step in-depth knowledge of the real capacities of this equipment. PreciseInhale[®] is the perfect multifunctional tool, that will become central in our developments of formulations for inhalation.”

(Stockholm, Sweden, 28 maj, 2021) ISAB:s ansökan för klinisk prövning av dess aerosolgenererings-system PreciseInhale[®] har godkänts av Läkemedelsverket. Manoush Masarrat (VD): ”Detta är en mycket viktig milstolpe för oss, både strategiskt och vetenskapligt. En lyckad klinisk validering kan transformera ISAB och öppna upp en helt ny klinisk marknad värderad i miljarder SEK.”

(Stockholm, Sweden, May 28, 2021) ISAB’s Clinical Trial Application to conduct a clinical trial of its aerosol generating system PreciseInhale[®] has been approved by the Swedish Medical Product Agency (Läkemedelsverket). CEO Manoush Masarrat: “This is a huge milestone for us. Successful clinical validation could be transformational for ISAB, unlocking new markets valued at several billion SEK, and opening up a wide range of new growth avenues.”

(Stockholm, Sweden, May 25, 2021) The agreement grants Sanyo Trading exclusive sales rights to ISAB instruments in Japan, with a minimum purchasing commitment of 3 000 000 SEK in 2021 and a minimum of 5 000 000 SEK in 2022.

(Stockholm, Sweden, May 19, 2021) Prominent experts and KOLs from universities across Europe have joined Inhalation Sciences’ new Scientific Advisory Board. The Board will meet first on June 1, 2021.

(Stockholm, Sverige, 19 maj 2021) Inhalation Sciences AB meddelar att bolagets delårsrapport för första kvartalet finns nu tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 19 May, 2021) Inhalation Sciences AB announces that the company's Q1 Report for 2021 (in Swedish) is now available on the company's website.

Inhalation Sciences AB meddelar att bolagets årsredosvisning för 2020 nu finns tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 14 May, 2021) Inhalation Sciences AB announces that the company's Annual Report for 2021 (in Swedish) is now available on the company's website.

(Stockholm 5 Maj, 2021) ISAB:s uppdragsforskningsenhet, Inhalation Research Services (IRS), har tecknat en ny order värd 29 700 EUR. Ordern består av preklinisk utvärdering med PreciseInhale[®], samt avancerad upplösnings- och absorptionsstudie med DissolvIt[®], ISAB:s ledande in vitro system som levererar exakta, prediktiva klinik-lika data, vilka signifikant kan reducera riskerna för misslyckande i kommande kliniska studier.

(Stockholm 5 May, 2021) Inhalation Research Services (IRS), ISAB’s contract research organization, has signed a new order worth 29.7 KEUR. The order includes key preclinical feasibility evaluations, to be carried out on PreciseInhale[®], and an advanced dissolution and absorption study on DissolvIt[®], ISAB’s leading in vitro tool which delivers exceptionally precise, predictive and life-like data, significantly reducing the risk of clinical failure in later trials.

Aktieägarna i Inhalation Sciences Sweden AB (publ), org.nr 556665-6038, kallas härmed till årsstämma den 8 juni 2021.

(Stockholm, Sweden, April 22, 2021) ISAB has signed an exclusive distribution agreement with Apex Inhalation, a spinoff of Apex Chromatography, one of South Asia’s leading suppliers of laboratory equipment. The region is one of the world’s largest and fastest-growing inhalation R&D markets with many global pharma companies having large-scale research and manufacturing facilities there. The agreement covers India, Bangladesh and Sri Lanka, and the potential in sales of instruments and services is estimated at over 3 MSEK for the rest of 2021 and 2022.

(Stockholm, Sweden, April 20, 2021) Inhalation Sciences (ISAB) has signed an agreement with prestigious lead generation company Cience and with Coelus Bio, a boutique CRO consulting firm specialized in inhalation drug development, to generate new leads and sales in the US. It is part of the marketing activities aimed at growing ISAB’s sales and presence in the US, a strategic goal for 2021, and becoming a clear market leader in its niche.

(Stockholm, Sverige, 20 april, 2021) Inhalation Sciences (ISAB) har signerat avtal med det prestigefulla lead- genereringsföretag Cience och med Coelus Bio, ett konsultföretag specialiserad på att generera leads och försäljning av kontraktsforskning inom inhalationsläkemedelsutveckling, båda verksamma på den amerikanska marknaden. Detta är en del av de marknadsaktiviteter som syftar till att öka antal leads och försäljningar på den amerikanska marknaden, vilket är ett av ISAB:s strategiska mål för 2021, samt att etablera sig som marknadsledande inom sin nisch.

(Stockholm, Sverige, april 06, 2021) Inhalation Sciences Sweden AB (ISAB) har skickat in en ansökan till Svenska Läkemedelsverket för godkännande av att påbörja en klinisk prövning av aerosolgenererings-systemet PreciseInhale[®].  

(Stockholm, Sweden, April 6, 2021) Inhalation Sciences Sweden AB has submitted a CTA (Clinical Trial Application) to the Swedish Medical Product Agency (Läkemedelsverket) for authorization to conduct a clinical trial of its aerosol generating system PreciseInhale[®].

Summary of the year-end report • ISAB has repositioned its CRO business under a new brand name, "Inhalation Research Services", or IRS, offering precise, predictive early-stage research data. • ISAB has installed the first DissolvIt[®] module at a laboratory at an international company in Switzerland. • ISAB has recruited Chief Commercial Officer to strengthen the commercial organization. • ISAB has recruited a Quality and Regulatory Affairs manager to strengthen the organization's regulatory and quality system and support the planned clinical trial. • The company's Board has held its annual strategy meeting and agreed on ISAB's strategic plan and priorities during 2021 and 2022.

Sammanfattning av delårsrapporten · ISAB har repositionerat sin CRO verksamhet under nytt varumärke till "Inhalation Research Services", eller IRS, viket erbjuder precisa och förutsägbara early-stage forskningsdata. · ISAB har installerarat den första DissolvIt®-modulen vid ett laboratorium på internationellt företag i Schweiz. · ISAB har rekryterat Chief Commercial Officer för att stärka den kommersiella organisationen. · ISAB har rekryterat kvalitetsansvarig för att stärka organisationens regulatoriska- och kvalitetssystem samt supportera den planerade kliniska prövningen. · Bolagets styrelse har haft sitt årliga strategimöte och enats om ISABs strategiska plan och prioriteringar under 2021 och 2022.

Inhalation researcher Snezana Radivojev from Graz University’s Research Center for Pharmaceutical Engineering (RCPE) has completed a month’s onsite contract research at ISAB’s labs in Stockholm working with the advanced in vitro solution tool DissolvIt[®]. As an in vitro specialist she has spent four years researching a wide range of lung models. How did DissolvIt[®] measure up, and how does her own experience of asthma feed into her research?

(Stockholm, 10 February 2021) PreciseInhale[®], Inhalation Sciences’ flagship high-precision aerosol generator for preclinical respiratory research, has received an extended international Registered Trademark from the International Bureau of the World Intellectual Property Organization (WIPO). ISAB CEO Manoush Masarrat: “This will play an important role in protection of our trademark and driving the growth of PreciseInhale[®] in many strategic global markets.”

Inhalation Sciences (ISAB) has appointed Helen Bäckroos as its Quality and Regulatory Affairs Manager. Ms Bäckroos, currently a Senior Consultant at Scandinavian Regulatory Services AB, takes up her post on February 15[th], 2021. The new role is crucial to ISAB’s ongoing expansion as PreciseInhale[®] begins trials for clinical validation in Q1 2021 and global product sales continue to grow.

(Stockholm, 18 December 2020) Innovative inhalation pharmaceutical technology company Aquilon Pharma, based in Belgium, has signed a purchase order for ISAB’s high-precision R&D system PreciseInhale[®], plus its Nose-Only and Intratracheal Exposure Modules. The combined value of the order is 292 KEUR.

(Stockholm, 18 december 2020) Det innovativa pharmatech-företaget Aquilon Pharma, baserad i Belgien, har signerat en köporder på ISAB´s högprecision system PreciseInhale[®] och dess Nose-Only samt Intratrakeala exponeringsmoduler. Det sammanlagda värdet på ordern är 292 KEUR. 

Inhalation Sciences (ISAB) has appointed global branding agency UP THERE, EVERYWHERE (UP) for a new digital marketing strategy that will include lead generation process, SEO (Search engine Optimisation) and highlighting of ISAB’s Unique Selling Points. 2020 has been a year of robust growth for ISAB and in its strategic plan for 2021, the company has identified the increase of  its digital brand and marketing capabilities as a clear priority in moving towards growing sales and leadership within its field.

(Stockholm, Sverige, 11 december 2020) Inhalation Sciences AB (ISAB) har erhållit information om att Georg Petersen har per idag, 2020/12/11, köpt totalt 503 750 ISAB aktier.

Inhalation Sciences (ISAB) has appointed Paolo Raffaelli as its new Chief Commercial Officer (CCO). Mr Raffaelli has extensive experience driving international sales in a wide range of medical device companies and takes up his position on December 14, 2020.

(Stockholm, Sverige, 26 november 2020) Sammanfattning av delårsrapporten: ISAB repositionerar sin CRO verksamhet under nytt varumärke till "Inhalation Research Services", eller IRS, viket erbjuder precisa och förutsägbara early-stage forskningsdata. ISAB installerar den första DissolvIt®-modulen vid ett laboratorium på internationellt företag i Schweiz. ISAB har påbörjat en rekryteringsprocess av försäljningschef för att stärka den kommersiella organisationen. ISAB har påbörjat en rekryteringsprocess av kvalitetsansvarig för att stärka organisationens regulatoriska- och kvalitetssystem samt supportera den planerade kliniska prövningen. Bolagets styrelse har haft sitt årliga strategimöte och enats om ISABs strategiska plan och prioriteringar under 2021 och 2022.

(Stockholm, Sweden, November 26, 2020) During the third quarter 2020, Inhalation Sciences repositioned its CRO business under a new brand name – ‘Inhalation Research Services’, or IRS, offering precise, predictive early-stage research data. ISAB installed its first DissolvIt® module in the laboratory of an international company in Switzerland. ISAB has initiated the recruitment process for a Director of Sales to strengthen its commercial organization, as well as a Regulatory and Quality manager to strengthen the team and support the planned clinical trial of PreciseInhale. The company's Board held its annual strategy meeting and agreed on ISAB's strategic plan and priorities during 2021 and 2022.

Inhalation Sciences (ISAB) and Astra Zeneca have published results from a landmark study into the pharmacokinetics of inhaled substances administered by PreciseInhale[®] to pigs, whose respiratory tracts closely resemble that of humans. CEO Manoush Masarrat “This is of major significance as we move forward towards clinical validation of PreciseInhale[®].”

Inhalation Sciences (ISAB) och AstraZeneca har publicerat resultat från en studie av farmakokinetikdata från grisar som inhalerat substanser levererade med PreciseInhale[®]. Grisars andningsvägar är till stora delar mycket lik människans. VD Manoush Masarrat “Detta är av stor betydelse då vi närmar oss den kliniska valideringen av PreciseInhale[®]”.